Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Emerging Company Policy Deconstructed: Start-up Jobs and Innovation Act (S. 1658)

Cancer

In a nutshell: Senators Robert Menendez (D-NJ) and Pat Toomey (R-PA) introduced the Start-up Jobs and Innovation Act to spur capital formation for R&D-focused companies in the early stages of development. Why you should care: It can take over a decade and cost more than $1 billion to bring a single groundbreaking biotechnology treatment from laboratory bench to hospital bedside, and virtually the entire process is funded by private investment. The Start-up Jobs and Innovation Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Innovation Is… with Doug Doerfler of MaxCyte

Inn-doug115x76

The term innovation is thrown around more often than Peyton Manning’s name during Fantasy Football season. But if any industry can truly capture the essence of innovation, it is the biotech industry. Innovation is inherent in what we do – from curing or treating illnesses that were once considered a death sentence to feeding a growing population to helping to reduce our dependence on foreign oil through the production of biofuels. But what is innovation, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Innovation Is… with David Pyott of Allergan, Inc

David Pyott

The term innovation is thrown around more often than Peyton Manning’s name during Fantasy Football season. But if any industry can truly capture the essence of innovation, it is the biotech industry. Innovation is inherent in what we do – from curing or treating illnesses that were once considered a death sentence to feeding a growing population to helping to reduce our dependence on foreign oil through the production of biofuels. But what is innovation, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Innovation Is… with Stephan Tanda, Managing Board Member, Royal DSM

ST-115x76

The term “innovation” is thrown around more often than Peyton Manning’s name during Fantasy Football season. But if any industry can truly capture the essence of innovation, it is the biotech industry. Innovation is inherent in what we do – from curing or treating illnesses that were once considered a death sentence to feeding a growing population to helping to reduce our dependence on foreign oil through the production of biofuels. But what is innovation, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

JOBS Act Deconstructed: Confidential Filing

AB23475

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. Any company conducting a public offering must file a registration statement, called an S-1, with the SEC.  The purpose of this document is to inform investors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,